The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of cladribine and low-dose AraC alternating with decitabine in older patients with AML.
Tapan M. Kadia
No relevant relationships to disclose
Jorge E. Cortes
No relevant relationships to disclose
Gautam Borthakur
No relevant relationships to disclose
Guillermo Garcia-Manero
No relevant relationships to disclose
Elias Jabbour
No relevant relationships to disclose
Alessandra Ferrajoli
No relevant relationships to disclose
Srdan Verstovsek
No relevant relationships to disclose
Farhad Ravandi
No relevant relationships to disclose
Naveen Pemmaraju
No relevant relationships to disclose
Naval Guastad Daver
No relevant relationships to disclose
Marina Konopleva
No relevant relationships to disclose
Xuemei Wang
No relevant relationships to disclose
Hagop M. Kantarjian
No relevant relationships to disclose